Results 91 to 100 of about 100,641 (375)
Long‐term safety and efficacy of levodopa‐carbidopa intestinal gel in advanced Parkinson's disease
Movement Disorders, 2018 Background: Levodopa‐carbidopa intestinal gel (designated as carbidopa‐levodopa enteral suspension in the United States) provides stable plasma levodopa concentrations and reduces motor fluctuations in advanced Parkinson's disease patients through ...
H. Fernandez +15 more
semanticscholar +1 more source
Fiber‐type soft bioelectronics for wearable and implantable sensing and therapy
BMEMat, EarlyView.Fiber‐type soft bioelectronics are emerging as versatile platforms for wearable and implantable health monitoring and therapeutic applications. These bioelectronics use organic and inorganic matrices combined with advanced fillers, which feature high conductivity, electrochemical sensitivity, softness, and biocompatibility.
Haneul Kim +5 more
wiley +1 more source
Frontiers in Neurology, 2019 Although the administration of dopamine precursor levodopa remains as the mainstay for the treatment of Parkinson's disease, long-term exposure to levodopa often causes a disabling complication, referred to as levodopa-induced dyskinesias. Therefore, the
Masatoshi Ogawa +9 more
doaj +1 more source
Levodopa‐Induced Neuropathy: A Systematic Review
Movement Disorders Clinical Practice, 2018 Clinical, neurophysiological, and pathological evidence suggest an association between Parkinson's disease (PD) and peripheral neuropathy (PNP), with a possible causative role of levodopa metabolic products, such as homocysteine and methylmalonic acid.
A. Romagnolo +5 more
semanticscholar +1 more source
BMEMat, EarlyView.This review provides an overview of the properties, composites and application of two‐dimensional (2D) nanomaterials for wearable electrochemical biosensors. Also, the challenges and future prospects of utilizing 2D nanomaterials in wearable electrochemical biosensor applications are discussed.
Kou Zhang +8 more
wiley +1 more source
Extended-release oral capsule of carbidopa–levodopa in Parkinson disease
Therapeutic Advances in Neurological Disorders, 2018 Motor fluctuations complicate the treatment of patients with Parkinson’s disease receiving levodopa. Extended-release carbidopa–levodopa has a pharmacokinetic profile that provides a more continuous levodopa serum concentration.
Jason Margolesky, Carlos Singer
doaj +1 more source
Treatment initiation for parkinson’s disease in Australia 2013–2018: a nation-wide study
BMC Geriatrics, 2022 Background Guidelines highlight the importance of an individualized approach to treatment initiation for Parkinson’s disease. Our aim was to investigate initiation of anti-Parkinson medication in Australia from 2013–2018, and to determine factors ...
Marjaana Koponen +5 more
doaj +1 more source
Tocotrienols: A Review From Source to Therapeutic Applications
Food Frontiers, EarlyView.Tocotrienols demonstrate superior antioxidant, neuroprotective, and anti‐inflammatory properties compared to conventional vitamin E forms, with promising therapeutic applications across multiple disorders when delivered through optimized systems that enhance their inherently limited bioavailability.
Natalia‐Carolina Londoño +6 more
wiley +1 more source
Effect of Rectal Levodopa Administration: A Case Report
Case Reports in Neurology, 2015 Objective: The aim of this report is to discuss whether or not rectal levodopa administration is useful in some situations. Background: In situations where oral intake of levodopa formulations is not possible, the treatment options of Parkinson's disease
Jolanda M.J. Vogelzang +2 more
doaj +1 more source
Orthostatic stability with intravenous levodopa [PDF]
PeerJ, 2015 Intravenous levodopa has been used in a multitude of research studies due to its more predictable pharmacokinetics compared to the oral form, which is used frequently as a treatment for Parkinson’s disease (PD).
Shan H. Siddiqi +2 more
doaj +2 more sources